Dysregulation of LPL activity can lead to atherogenic dyslipidemia, characterized by elevated TG and reduced HDL-C levels, which are hallmark features of metabolic syndrome and associated with increased cardiovascular risk [32]. This evidence concerns the gene LPL and metabolic syndrome.